Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
Lineage Commitment01:21

Lineage Commitment

3.6K
Commitment is the  process whereby stem cells:
3.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients.

Cells·2026
Same author

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Leukemia·2026
Same author

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Leukemia·2026
Same author

The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial.

Cells·2025
Same author

Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission.

Clinical and experimental medicine·2025
Same author

Bringing global hematology research to the forefront.

Blood advances·2024

相关实验视频

Updated: Oct 23, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

慢性骨髓性白血病

Jorge Cortes1, Carolina Pavlovsky2, Susanne Saußele3

  • 1Georgia Cancer Center, Augusta University, Augusta, GA, USA.

Lancet (London, England)
|August 23, 2021
PubMed
概括

铁酶抑制剂在慢性骨髓性白血病患者中提供了接近正常的预期寿命. 对新药和治疗策略的持续研究可能会为更多的患者带来治愈.

科学领域:

  • 血液学
  • 癌症学
  • 药理学

背景情况:

  • 慢性骨髓性白血病 (CML) 的治疗已经由氨酸激酶抑制剂 (TKIs) 彻底改变.
  • 多种TKI显著改善了患者的治疗结果,导致许多患者的预期寿命接近正常.
  • 有效的CML治疗需要一种不仅仅是药物的综合方法.

研究的目的:

  • 审查TKI对CML自然史的影响.
  • 概述在CML中实现最佳治疗反应和长期存活的关键组成部分.
  • 讨论目前和新兴的CML治疗策略,包括停止治疗和新药.

主要方法:

  • 对慢性髓性白血病的氨酸激酶抑制剂治疗现有文献的综述.
  • 影响治疗成功的因素分析,包括患者监测,不良事件管理和并发症.
  • 讨论不断变化的治疗模式,如治疗停止和新药的开发.

主要成果:

  • 经过适当的治疗,慢性髓性白血病患者可以获得接近正常的预期寿命.
  • 最佳反应标志,不良事件管理和并发症确认对于成功的TKI治疗至关重要.
  • 对于一些CML患者来说,无需治疗的缓解正在成为一种可能性,并且正在开发针对耐药病例的新药.

更多相关视频

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K

相关实验视频

Last Updated: Oct 23, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.7K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K

结论:

  • 氨酸激酶抑制剂使慢性骨髓性白血病转变为可控的疾病,生存率高.
  • 个性化治疗策略,包括对副作用和并发症的仔细监测和管理,至关重要.
  • 对于大多数患者来说,CML治疗的进展,包括停止治疗的可能性和新疗法,为最终治愈提供了希望.